



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

## BIB DATA SHEET

CONFIRMATION NO. 8473

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.		
10/592,994	03/23/2007 RULE	514	1614	VER-209XX		
<b>APPLICANTS</b> Willem Ferdinand Nieuwenhuizen, Bunnik, NETHERLANDS; Aloysius Maria Havekes, Alphen aan den Rijn, NETHERLANDS; Josephus Jan Emeis, Amsterdam, NETHERLANDS;						
<b>** CONTINUING DATA *****</b> This application is a 371 of PCT/NL05/00193 03/15/2005						
<b>** FOREIGN APPLICATIONS *****</b> EUROPEAN PATENT OFFICE (EPO) 04075848.4 03/16/2004 EUROPEAN PATENT OFFICE (EPO) 04077088.5 07/19/2004						
<b>** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **</b> 05/26/2007						
Foreign Priority claimed 35 USC 119(a-d) conditions met Verified and Acknowledged	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No /TIMOTHY P THOMAS/ Examiner's Signature	<input type="checkbox"/> Met after Allowance Initials	<b>STATE OR COUNTRY</b> NETHERLANDS	<b>SHEETS DRAWINGS</b> 2	<b>TOTAL CLAIMS</b> 11	<b>INDEPENDENT CLAIMS</b> 8
<b>ADDRESS</b> WEINGARTEN, SCHURGIN, GAGNEBIN & LEBOVICI LLP TEN POST OFFICE SQUARE BOSTON, MA 02109 UNITED STATES						
<b>TITLE</b> Use of Sphingolipids in the Treatment and Prevention of Type 2 Diabetes Mellitus, Insulin Resistance and Metabolic Syndrome						
<b>FILING FEE RECEIVED</b> 2030	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees			
			<input type="checkbox"/> 1.16 Fees (Filing)			
			<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)			
			<input type="checkbox"/> 1.18 Fees (Issue)			
			<input type="checkbox"/> Other _____			
			<input type="checkbox"/> Credit			